📰 Foundationone Liquid News
Page 2 - Foundationone Liquid News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Foundationone Liquid. Real-time updates on events, politics, business and more.
August 10, 2023
The global liquid biopsy market was estimated at USD 4,722.73 million in 2022 and is anticipated to hit around USD 18,280.13 million by 2032, registering a...
June 5, 2023
The companies will develop FoundationOne Liquid CDx and FoundationOne CDx as CDx tests in the US market for selected Merck KGaA marketed and pipeline treatments.
May 31, 2023
The combination of panitumumab and standard-of-care trifluridine-tipiracil rechallenge delivered a progression-free survival benefit vs trifluridine-tipiracil alone in the third-line setting in patients with refractory RAS wild-type metastatic colorectal cancer, meeting the primary end point of the phase 2 VELO trial.
May 29, 2023
/PRNewswire/ -- The "Multicancer Screening Market - A Global and Regional Analysis: Focus on Test Type, Technology, Sample, Method, Cancer Type, Application,...
April 28, 2023
/PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Multicancer...
April 28, 2023
New discoveries of specific biomarkers related to various cancer types are increasing researchers' trust in multicancer sequencing. FREMONT, Calif., April 28, 2023 /PRNewswire/ -- BIS Research
January 4, 2023
FoundationOne Liquid CDx, a liquid biopsy test, is the only blood-based CDx approved for the targeted cancer therapy.
December 21, 2022
The FoundationOne Liquid CDx test can be used with Tarceva (erlotinib), Tagrisso (osimertinib), and Iressa (gefitinib), and other TKIs approved in the future.
December 21, 2022
The FoundationOne Liquid CDx test can be used with Tarceva (erlotinib), Tagrisso (osimertinib), and Iressa (gefitinib), and other TKIs approved in the future.